Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV is experiencing significant developments in its gene therapy pipeline, particularly highlighted by the robust efficacy data from AMT-130, which the management asserts represents a groundbreaking standard within the Huntington's disease community. The ongoing collaborations, particularly with Bristol Myers Squibb, enhance the company's capabilities in addressing cardiovascular diseases, while recent trial expansions for AMT-260 in mesial temporal lobe epilepsy demonstrate a proactive approach to broadening its therapeutic portfolio. Despite increased SG&A expenses, the management's emphasis on AMT-130's favorable risk-benefit profile and the absence of regulatory concerns suggests a sustainable pathway forward, reinforcing a positive long-term outlook for the company's operational and financial performance.

Bears say

uniQure NV faces significant challenges that negatively impact its outlook, primarily due to delays in the Biologics License Application (BLA) submission, which management has withdrawn from its previous guidance. The company's positioning is further weakened by the competitive landscape, as existing and emerging therapies threaten its market share and pricing strategies. Financially, uniQure remains a clinical stage company without any revenue-generating products and has consistently incurred losses, exacerbated by the potential for extended development timelines and increased costs amid ongoing clinical setbacks.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.